Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 high-risk subgroup analysis Meeting Abstract
| Authors: | Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M.; Cavo, M.; Callander, N.; Costa, L.; Moreau, P.; Solomon, S.; Chen, C.; Raje, N.; Scheid, C.; Delforge, M.; Larsen, J.; Pabst, T. M.; Suzuki, K.; Truppel-Hartmann, A.; Yang, Z.; Piasecki, J.; Felten, J.; Caia, A.; Cook, M.; Giralt, S.; Mateos, M. V. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 high-risk subgroup analysis |
| Meeting Title: | 20th Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Sep 27-30 |
| Meeting Location: | Athens, Greece |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S56 |
| End Page: | S57 |
| Language: | English |
| ACCESSION: | WOS:001079705400092 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01658-0 |
| Notes: | Meeting Abstract: P-040 -- Source: Wos |
